Enterprise Innovation

A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine.

Nearly 200 scientists, investors and industry representatives attended Weill Cornell Medicine’s 2025 Biomedical Innovation Conference April 1, sharing their startup journeys and experiences nurturing biomedical advances into health care products and companies.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.

The distinct population of endothelial cells that line blood vessels in the insulin-producing “islets” of the human pancreas have been notoriously difficult to study, but Weill Cornell Medicine investigators have now succeeded in comprehensively detailing the unique characteristics of these cells. 

In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.

A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according to a study led by Weill Cornell Medicine researchers.

Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses. 

Endothelial cells with a distinct gene-expression signature play a key role in the development and repair of blood vessels throughout life, according to a new study by Weill Cornell Medicine investigators. 

The 2024 Business Plan Challenge accelerator program culminated in a pitch competition with five finalist teams putting their knowledge and marketing skills to the test. 

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center and Memorial Sloan Kettering Cancer Center.

Weill Cornell Medicine scientists have uncovered the first evidence that astrocyte receptors can trigger opposite effects on cognitive function in male and female preclinical models.

A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. 

The Dean’s Symposium  on Innovation and Entrepreneurship, which took place Nov. 7, celebrated innovation and Weill Cornell Medicine’s entrepreneurial spirit.

A $20 million gift from Andrew H. ’71 and Ann R. Tisch will foster engagement and collaboration between Cornell Tech and Weill Cornell Medicine, catalyzing new discoveries at the intersection of health and technology.

Dr. Sheila Nirenberg, the Nanette Laitman Professor of Neurology and Neuroscience and a professor of physiology and biophysics at Weill Cornell Medicine, has received the Barbara McClintock Women Innovator Award at the Inaugural Women Innovator Awards.

A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge.